Insider Selling: Penumbra, Inc. (PEN) Director Sells 345 Shares of Stock
Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 345 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $90.20, for a total value of $31,119.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Thomas Wilder also recently made the following trade(s):
- On Tuesday, July 18th, Thomas Wilder sold 345 shares of Penumbra stock. The shares were sold at an average price of $86.10, for a total value of $29,704.50.
Penumbra, Inc. (NYSE:PEN) traded up 1.36% during midday trading on Wednesday, reaching $92.85. The company had a trading volume of 79,116 shares. Penumbra, Inc. has a 1-year low of $56.05 and a 1-year high of $93.10. The firm has a 50-day moving average of $87.45 and a 200 day moving average of $85.29. The company has a market capitalization of $3.14 billion, a P/E ratio of 627.36 and a beta of 0.09.
Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $80.60 million during the quarter, compared to analysts’ expectations of $77.16 million. Penumbra had a negative return on equity of 2.58% and a negative net margin of 2.78%. The firm’s quarterly revenue was up 23.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.01 EPS. On average, equities research analysts forecast that Penumbra, Inc. will post ($0.21) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Penumbra, Inc. (PEN) Director Sells 345 Shares of Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/insider-selling-penumbra-inc-pen-director-sells-345-shares-of-stock.html.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Penumbra by 10.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock worth $102,000 after purchasing an additional 114 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Penumbra in the first quarter valued at about $194,000. Verition Fund Management LLC purchased a new stake in Penumbra in the second quarter valued at about $213,000. FNY Partners Fund LP purchased a new stake in Penumbra in the first quarter valued at about $223,000. Finally, Prudential Financial Inc. purchased a new stake in Penumbra in the second quarter valued at about $252,000. Hedge funds and other institutional investors own 70.93% of the company’s stock.
PEN has been the subject of several analyst reports. BidaskClub downgraded Penumbra from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Canaccord Genuity restated a “buy” rating and set a $94.00 price target on shares of Penumbra in a report on Tuesday, June 13th. BMO Capital Markets restated a “buy” rating and set a $96.00 price target on shares of Penumbra in a report on Friday, June 16th. Finally, Zacks Investment Research upgraded Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, August 30th.
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.